STOCK TITAN

Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

TLSA Nasdaq

Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.

Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biotechnology innovator developing intranasal immunotherapies for neurodegenerative and inflammatory diseases. This page provides centralized access to official corporate announcements, clinical trial updates, and strategic developments.

Investors and researchers will find timely updates on TLSA's novel drug delivery platform, including progress with intranasal foralumab and other candidates targeting multiple sclerosis, Alzheimer's, and autoimmune conditions. The repository includes press releases on FDA communications, partnership announcements, and peer-reviewed research findings.

Key content categories include clinical trial milestones, intellectual property updates, executive leadership changes, and financial performance reports. All materials are sourced directly from the company and verified financial news outlets to ensure accuracy.

Bookmark this page for streamlined tracking of TLSA's progress in advancing non-invasive immunotherapy solutions. Check regularly for updates on groundbreaking approaches to modulating immune responses through nasal administration.

Rhea-AI Summary

Tiziana Life Sciences Plc has initiated a strategic restructuring, transitioning to Tiziana Life Sciences Ltd, a Bermuda-based parent company. This move was approved by Scheme Shareholders with 99.11% support at the Court Meeting and a requisite majority at the General Meeting. The Scheme is pending court sanction on October 19, 2021, with an expected effective date of October 21, 2021. The transition will involve the delisting of Old Tiziana shares from the London Stock Exchange and NASDAQ, paving the way for trading of New Tiziana shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
-
Rhea-AI Summary

Tiziana Life Sciences (NASDAQ: TLSA) announced its interim results for the six months ending June 30, 2021, highlighting significant advancements in therapeutic clinical programs. The Phase 1 study of Foralumab demonstrated immunomodulatory effects, while a study in Brazil showed promising outcomes for COVID-19 patients. The company signed an agreement for a Phase 2 study in severe COVID-19 cases and initiated a study for multiple sclerosis. Financially, Tiziana reported a loss of £12.59 million, with R&D expenses increasing to £12.6 million. The firm had cash reserves of £38.6 million at the period's end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
none
-
Rhea-AI Summary

Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) will host a conference call on September 8, 2021, at 4:15 p.m. ET to discuss its exclusive license agreement for evaluating Foralumab, a novel anti-CD3 monoclonal antibody, alongside CAR T candidates for cancer treatment. Interested parties can join via a toll-free line or webcast. A replay will be available until September 22, 2021. Foralumab is recognized for its safety profile in treating autoimmune diseases, making it a significant development in biotechnology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.33%
Tags
conferences
Rhea-AI Summary

Tiziana Life Sciences plc (NASDAQ: TLSA) announced the initiation of a strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd in Bermuda as its ultimate parent company. This restructuring, carried out through a scheme of arrangement, aims to enhance the organization’s operational efficiency. Shareholders are invited to virtual meetings on September 27, 2021, to vote on the scheme. Key dates include the effective date for the scheme on October 21, 2021, and the delisting of Old Tiziana Shares and ADSs on the same day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
-
Rhea-AI Summary

Precision BioSciences has secured an exclusive license for Tiziana Life Sciences’ anti-CD3 monoclonal antibody, Foralumab, to evaluate its use as a lymphodepletion agent alongside its allogeneic CAR T therapies for cancer treatment. This collaboration aims to enhance the efficacy of CAR T cell therapies by potentially improving their durability and clinical outcomes. Precision will assume development and commercialization duties, while Tiziana will receive upfront and milestone payments along with royalties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.21%
Tags
none
-
Rhea-AI Summary

Precision BioSciences (Nasdaq: DTIL) has secured an exclusive license from Tiziana Life Sciences (Nasdaq: TLSA) to utilize foralumab, a human anti-CD3 monoclonal antibody, as a lymphodepletion agent in its allogeneic CAR T therapy development. The collaboration aims to enhance the therapeutic effectiveness of CAR T cells by improving their tolerance and long-term persistence. Precision will oversee the development and commercialization of foralumab, providing Tiziana with upfront, milestone, and royalty payments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.21%
Tags
none
Rhea-AI Summary

Tiziana Life Sciences plc (NASDAQ: TLSA) announced a strategic reorganization to establish Tiziana Life Sciences Ltd, a Bermuda-incorporated parent company. This change aims to align the company's listing with its primary US operations and facilitate a direct NASDAQ listing. Old Tiziana shareholders will exchange their shares for New Tiziana Shares at a 2-for-1 ratio, and Old Tiziana will then delist from the FCA and London Stock Exchange. The restructuring is expected to enhance liquidity and reduce costs for shareholders, with details of the scheme and necessary approvals to be communicated soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.97%
Tags
none
-
Rhea-AI Summary

Tiziana Life Sciences (TLSA) announced the successful results of its pilot study on Foralumab, an intranasal anti-CD3 monoclonal antibody for COVID-19 treatment. The study showed a significant reduction in lung inflammation and pro-inflammatory biomarkers, including IL-6 and CRP. Treatment was well-tolerated with only mild adverse events reported. Following this, Tiziana plans to initiate a Phase 2 study in Brazil to further evaluate Foralumab's safety and efficacy in hospitalized COVID-19 patients. The promising data suggests a potential therapeutic benefit for immune hyperactivity in severe cases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced its ADS will trade ex-dividend from July 9, 2021. The non-cash dividend will consist of one Accustem Sciences Limited ADS, equivalent to two ordinary shares, for each TLSA ADS held. Payment of the dividend is scheduled for July 14, 2021. Shareholders who acquired TLSA ADS before the ex-dividend date are eligible for this dividend. For more details, refer to JP Morgan's notice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
Rhea-AI Summary

Tiziana Life Sciences plc (Nasdaq: TLSA) announced that the SEC has declared effective the Forms 20-F and F-6 filed by Accustem Sciences Limited, allowing the completion of the spin-off of Accustem. Key dates include the demerger record time on October 30, 2020, and the issuance of Accustem shares to Tiziana shareholders starting July 8, 2021. Existing Tiziana DRs will remain valid without requiring exchange for new DRs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none

FAQ

What is the current stock price of Tiziana Life Sciences Com (TLSA)?

The current stock price of Tiziana Life Sciences Com (TLSA) is $1.48 as of July 11, 2025.

What is the market cap of Tiziana Life Sciences Com (TLSA)?

The market cap of Tiziana Life Sciences Com (TLSA) is approximately 176.4M.
Tiziana Life Sciences Ltd Com

Nasdaq:TLSA

TLSA Rankings

TLSA Stock Data

176.44M
68.85M
35.56%
0.89%
0.55%
Biotechnology
Healthcare
Link
United Kingdom
London